# Systematic modeling predicts synergistic and safe drug combinations for parasitic diseases

## TL;DR

A new AI framework called MetaSynMT predicts effective and safe drug combinations for parasitic diseases, validated by successful lab results.

## Contribution

MetaSynMT is a novel multi-task learning framework that jointly predicts drug synergy and side effects for parasitic diseases.

## Key findings

- MetaSynMT outperforms existing methods in predicting synergistic and safe drug combinations.
- The combination of allicin and sodium stibogluconate achieved 100% inhibition of echinococcosis parasites in vitro.
- The model shows strong generalization across diverse real-world settings.

## Abstract

Parasitic diseases impose a substantial global health burden due to the widespread transmission and diversity of protozoa and helminths, which cause numerous infections and regional outbreaks. Despite the availability of various antiparasitic drugs, their clinical utility is often constrained by high cost, toxicity, severe side effects, and the growing threat of drug resistance. Combination therapy, designed to enhance efficacy through synergistic effects while reducing toxicity, represents a promising strategy to improve treatment outcomes for parasitic diseases. In this work, we propose MetaSynMT, a novel multi-task learning framework designed to predict synergistic and safe drug combinations, with a specific focus on parasitic diseases. The model integrates a meta-path aggregation mechanism to capture both structural and high-order semantic features of drugs. Alongside the primary task of synergy prediction, we introduce a secondary task of side effect prediction, enabling the joint identification of combinations with high synergy and low toxicity. Experimental results demonstrate that MetaSynMT outperforms several state-of-the-art baselines on parasitic disease dataset and exhibits strong generalization capability across diverse real-world settings. Furthermore, based on MetaSynMT’s predictions, we identified allicin and sodium stibogluconate as a promising combination therapy for echinococcosis. In vitro protoscolex culture experiments showed that the combination achieved a 100% inhibition rate at concentrations of 850 μM allicin and 36.3 μM sodium stibogluconate, significantly surpassing monotherapies. Overall, this work provides a novel computational tool and theoretical foundation for optimizing antiparasitic drug combinations and discovering potential therapeutic strategies.

Parasitic diseases affect millions of people worldwide and remain a major public health challenge, especially in regions with limited medical resources. Current treatments are often expensive, toxic, and increasingly less effective due to the rise of drug resistance. Combining two or more drugs is a promising way to improve treatment, but identifying safe and effective combinations is difficult and usually relies on time-consuming laboratory testing.

In this study, we developed MetaSynMT, a new artificial intelligence framework that can predict both the effectiveness and the potential side effects of drug combinations for parasitic diseases. Our model not only performed better than existing methods on large datasets, but also suggested a novel therapy: the natural compound allicin combined with the clinical drug sodium stibogluconate. Laboratory experiments confirmed that this combination was highly effective against the parasite that causes echinococcosis, completely blocking its growth at tested doses.

By integrating advanced machine learning with experimental validation, our work provides a powerful tool for accelerating the discovery of new and safer treatments for parasitic diseases, offering hope for more accessible and effective therapies worldwide.